Ataluren
Translarna (ataluren) is a small molecule pharmaceutical. Ataluren was first approved as Translarna on 2014-07-31. It has been approved in Europe to treat duchenne muscular dystrophy.
Trade Name | Translarna |
---|---|
Common Name | Ataluren |
Indication | duchenne muscular dystrophy |
Drug Class | Inducers of ribossomal readthrough of nonsense mutation mRNA stop codons |